ArticleDrug delivery and translational research2012
Drug transport into the central nervous system: using newer findings about the blood-brain barriers.
Article in Drug delivery and translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner.Pharmaceutical research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barriers (BBBs) represent one of the biggest challenges for the effective delivery of drugs today. Discoveries made in the last 30 years offer new strategies for central nervous system (CNS) drug development, but have yet to be fully incorporated into the field. Here, we examine seven recently discovered aspects of the BBB and how they have been or could be developed for drug delivery. These areas are brain-to-blood (efflux) transporters, immune cell trafficking into the brain under physiologic conditions, mechanisms by which antibodies can access the CNS, Trojan horse delivery systems, blood-to-brain transport systems for biologicals, lectin interactions and ligand modifications that enhance BBB penetration, and secretory capacities of cells comprising the BBBs.
Identifiers
25786864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.